Investor Relations

Setting science in motion to create a better world

Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve.

Investor Day

Biopharma spotlight

We have deep ties to the scientific and pharma industries and are supporting key breakthroughs and life-changing treatments for patients. Biopharma accounts for more than 50% of our revenue. Our portfolio of nearly 6 million different products is used in virtually every stage of the most important research, development and production work, such as monoclonal antibodies, cell and gene therapy, vaccines.

2021 Financial Summary1

11.3%

Organic revenue
growth

~190bps

Adj. EBITDA margin expansion

57.7%

Adj. EPS
growth

~100%

Free Cash Flow
conversion2


1. See "Reconciliations of Non-GAAP measures" in our annual report on Form 10-K and our 4Q 2021 quarterly earnings materials for a discussion of non-GAAP measures.
2. Free Cash Flow conversion is defined as Free Cash Flow / Adj. Net Income. Included in 4Q 2021 earnings materials.

Latest News

All News

Featured Video

We Set Science in Motion to Create a Better World